Skip to contentA
Alnylam Pharmaceuticals, Inc.
A
ALNYAlnylam Pharmaceuticals, Inc. Q2 2018 · 10-Q
Revenue$29.91M$29.91M+87.7% vs Q2 2017 Net Income-$163.56M-$163.56MN/M vs Q2 2017 EPS Diluted-$1.63-$1.63N/M vs Q2 2017 Operating Income-$192,354,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$125,395,000N/M Margins · derivedOperating margin-643.2%+113.0 pt vs Q2 2017
Net margin-546.9%+196.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 2, 2018 · 33 d after period end